Murine polyomavirus and simian virus 40 were used to evaluate the potencies of the compounds of three classes of acyclic nucleoside phosphonates: (i) the original HPMP (3-hydroxy-2-phosphonomethoxypropyl) and PME (2-phosphonomethoxyethyl) derivatives, (ii) the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidine (DAPy) derivatives, and (iii) a new class of HPMP derivatives containing a 5-azacytosine moiety. The last class showed the highest activities and selectivities against both polyomaviruses.
, and their structures are shown in Fig. 1 . The murine polyomavirus strains, i.e., MN/RDE Toronto, PTA, 2PTA2, and LID-1 (ATCC VR-252), were grown in UC1-B cells (murine embryo fibroblasts, ATCC 6465-CRL). SV40 strain A2895 (ATCC VR-305), SV40 PML-1 strain EK (ATCC VR-820), and SV40 PML-2 strain DAR (ATCC VR-821) were propagated in BS-C-1 cells (African green monkey kidney cell line ATCC CCL-26). Cytopathic reduction assays were carried out as described previously (1) . The viral cytopathic effect (CPE) was recorded, and the 50% effective concentration (EC 50 ) was defined as the compound concentration required to reduce the viral CPE by 50% compared to that for the untreated control. The cell toxicities of the compounds were evaluated based upon inhibition of cell growth using a Coulter counter, and the evaluations were performed as reported before (1). The 50% cytotoxic concentration (CC 50 ) was defined as the concentration required to reduce the number of cells by 50% compared to that for the untreated control. The selectivity index (SI) was calculated as the ratio of the CC 50 for cell growth to the EC 50 for viral CPE. The antiviral activities of the three classes of ANPs against murine polyomavirus and SV40 strains are shown in Table 2 and Two DAPy derivatives (i.e., HPMPO-DAPy and PMEODAPy) of the second class of ANPs were included in this study.
The anti-murine polyomavirus activity of HPMPO-DAPy, with an average EC 50 of 11.1 Ϯ 2.3 M, was comparable to that of its alkyl purine counterpart (i.e., HPMPDAP) and to that of the reference compound HPMPC, whereas PMEO-DAPy (mean EC 50 of 14.7 Ϯ 5.1 M) proved to be as active as its PME counterpart. When the DAPy derivatives were tested against the three SV40 strains, HPMPO-DAPy (average EC 50 of 86.1 Ϯ 22.8 M) was observed to be two-and fivefold less active than HPMPDAP and HPMPC, respectively. PMEODAPy (average EC 50 of 156.3 Ϯ 21.9 M) showed, similar to its alkylpurine counterpart, i.e., PMEA, a weak activity. For both murine polyomavirus and SV40, none of the DAPy compounds were selective.
Among the HPMP derivatives containing a 5-azacytosine moiety, HPMP-5-azaC and cHPMP-5-azaC exhibited antipolyomavirus potencies similar to those of HPMPC and cHPMPC, respectively. With average SIs of 23 and 28, respectively, for murine polyomaviruses and SV40 strains, HPMP-5-azaC reduction assay, carried out as previously described (1) . As shown in Fig. 2 , HDE-cHPMP-5-azaC (EC 99 values of 0.81 M, 0.43 M, and 0.26 M against the LID-1, PTA, and SV40 A2895 strains, respectively) emerged as the most potent inhibitor of both murine polyomavirus ( Fig. 2A and B) and SV40 (Fig. 2C) As previously reported (1), we confirmed here that HPMPC and cHPMPC proved to be the most selective drugs of the first class of ANPs against both murine and primate polyomaviruses. They served as references for the evaluation of the two other classes of ANPs. Among them, the second class of ANPs (i.e., the DAPy derivatives), which has been shown to display antiviral activity spectra and potencies that closely resemble those of the parental HPMP-and PME-purine types of compounds (2, 4), also showed antipolyomavirus activities comparable to those of the parent compounds. However, none of the DAPy derivatives was selective against polyomaviruses. Recently, HPMP-5-azaC, the leading compound of the third class of ANPs, was shown to display antiviral activities against adeno-, pox-and herpesviruses comparable to, or even better than, those of the parent compound HPMPC (12, 13) . In the present study, we demonstrated that HPMP-5-azaC and cHPMP-5-azaC have antipolyomavirus potencies similar to those of HPMPC and cHPMPC, respectively. In order to increase the cellular uptake and oral bioavailability of HPMPC, several alkoxyalkyl esters have been designed. These compounds proved to be highly active and selective against adenovirus, poxviruses, human papillomavirus, cytomegalovirus, and herpes simplex virus (3, 7, 9, 15, 23) . When these prodrugs were given orally to treat cowpox and vaccinia virus infections in mice, they were as active as HPMPC given parenterally (18). Randhawa et al. recently showed that compounds obtained by esterification of HPMPC with octadecycloxyethyl, oleyloxyethyl, and hexadecycloxypropyl inhibited BKV replication in vitro up to 1,400-fold more than HPMPC (19) . In the present study, the alkoxyalkyl ester of cHPMP-5-azaC (HDE-cHPMP-5-azaC) was highly potent and selective against murine and primate polyomaviruses. This is in agreement with our observations for other DNA viruses (12) .
In conclusion, we have demonstrated that among the compounds of the three classes of ANPs that were analyzed here for their anti-murine polyomavirus and anti-SV40 activities, the HPMP derivatives bearing the 5-azacytosine moiety showed the highest activities and selectivities. Further studies are needed to determine the clinical potential for these compounds to become new drug candidates for treatment of polyomavirus-infected patients. Previously, it was demonstrated that the mechanisms of action of HPMPC against herpes-, poxand adenoviruses are based on the higher affinity of this compound for viral polymerases than for cellular DNA polymerases (5). Since polyomaviruses do not encode their own DNA polymerase, they depend on cellular DNA polymerases for their replication. Consequently, it is suggested that HPMPC might interfere with the function of viral and/or cellular proteins jointly involved in the replicative process of the virus. A potential target is the large T antigen, a viral oncoprotein that plays an essential role in viral DNA replication and modulates cellular signaling pathways (24) . Further studies are currently under way to elucidate the mechanisms of action of ANPs against polyomaviruses, including the selection of resistant viruses under selective drug pressure.
